Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Abstract

Background We developed a personalized Monocyte-Derived Dendritic-cell Therapy (MDDCT) for HIV-infected individuals on suppressive antiretroviral treatment and evaluated HIV-specific T-cell responses. Methods PBMCs were obtained from 10 HIV+ individuals enrolled in trial NCT02961829. Monocytes were differentiated into DCs using IFN-α and GM-CSF. After sequencing each patient’s HIV-1 Gag and determining HLA profiles, autologous Gag peptides were selected based on the predicted individual immunogenicity and used to pulse MDDCs. Three doses of the MDDCT were administered every 15 days. To assess immunogenicity, patients’ cells were stimulated in vitro with autologous peptides, and intracellular IL-2, TNF, and interferon-gamma (IFN-γ) production were measured in CD4+ and CD8+ T-cells. Results The protocol of ex-vivo treatment with IFN-α and GM-CSF was able to induce maturation of MDDCs, as well as to preserve their viability for reinfusion. MDDCT administration was associated with increased expression of IL-2 in CD4+ and CD8+ T-cells at 15 and/or 30 days after the first MDDCT administration. Moreover, intracellular TNF and IFN-γ expression was significantly increased in CD4+ T-cells. The number of candidates that increased in vitro the cytokine levels in CD4+ and CD8+ T cells upon stimulation with Gag peptides from baseline to day 15 and from baseline to day 30 and day 120 after MDDCT was significant as compared to Gag unstimulated response. This was accompanied by an increasing trend in the frequency of polyfunctional T-cells over time, which was visible when considering both cells expressing two and three out of the three cytokines examined. Conclusions MDDC had a mature profile, and this MDDCT promoted in-vitro T-cell immune responses in HIV-infected patients undergoing long-term suppressive antiretroviral treatment. Trial registration NCT02961829: (Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure, https://www.clinicaltrials.gov/ct2/show/NCT02961829, posted November 11th, 2016)

Immune-Related Gene Profile in HIV-Infected Patients with Discordant Immune Response

“…In contrast, certain studies have reported that this cytokine can increase the cytotoxic T lymphocytes and natural killer cell activities against HIV-1-infected cells. In addition, IFN-γ upregulates the MHC-II pathway supporting the antigen-specific activation of CD4 + T cells [24][25][26] . Research has exhibited that in primary HIV infection, ICAM-1 significantly increases and is involved in promoting inflammatory responses against HIV infection.…”

Dendritic cells: the yin and yang in disease progression

“…However, the discovery of the immunogenic capacity of DCs has been shown to be suitable for cancer therapy ( 20 ) and for other pathologies ( 21 ). In the last years, these immunogenic DCs have been used in personalized treatments in patients with HIV receiving antiretroviral treatment ( 22 ) or in ovarian cancer patients ( 23 ).…”

Next Generation Gold Drugs and Probes: Chemistry and Biomedical Applications

“…This study was later withdrawn. Researchers in Sao Paolo launched a clinical trial toward HIV cure by studying a combination therapy involving Maraviroc and/or dolutegravir, dendritic cell vaccination, class III histone deacetylases (HDACs), surtuin-1, and auranofin to decrease the ratio of long-lived central memory/transitional memory (TTM) CD4+ T-cells. , Although results are not yet available, a positive outcome will result in an efficacious combination treatment regimen for HIV sterilizing cure.…”